Company
Headquarters: Taichung, Taiwan
TW$1.09 Billion
TWD as of Jan. 1, 2026
US$34.9 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers pathogen detection platforms, including equipment and reagents; and animal use medicines, biotechnology services, medical materials and equipment, and precision instruments. The company also provides polymerase chain reaction training programs, molecular diagnostic technical solutions, laboratory installation services, OEM/ODM contract manufacturing services, and research collaboration services. It serves aquaculture, agriculture, food, and human health industries, as well as companion animals and livestock. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan.
GeneReach Biotechnology Corp has the following listings and related stock indices.
Stock: TWSE: 4171